{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T15:16:56Z","timestamp":1793459816593,"version":"4.5.0"},"reference-count":125,"publisher":"Elsevier BV","issue":"7","license":[{"start":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T00:00:00Z","timestamp":1656633600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,7,1]],"date-time":"2023-07-01T00:00:00Z","timestamp":1688169600000},"content-version":"am","delay-in-days":365,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","award":["2UL1 TR001445-06A1"],"award-info":[{"award-number":["2UL1 TR001445-06A1"]}],"id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","mayoclinicproceedings.org","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2022,7]]},"DOI":"10.1016\/j.mayocp.2022.02.027","type":"journal-article","created":{"date-parts":[[2022,7,1]],"date-time":"2022-07-01T10:11:45Z","timestamp":1656670305000},"page":"1345-1362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":52,"title":["Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications"],"prefix":"10.1016","volume":"97","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7565-1009","authenticated-orcid":false,"given":"Nicole","family":"Leung","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4011-6238","authenticated-orcid":false,"given":"Kevin","family":"Yip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3168-1542","authenticated-orcid":false,"given":"Michael H.","family":"Pillinger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4152-0232","authenticated-orcid":false,"given":"Michael","family":"Toprover","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1038\/s41572-019-0115-y","article-title":"Gout","volume":"5","author":"Dalbeth","year":"2019","journal-title":"Nat Rev Dis Primers"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib2","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1007\/s10067-019-04868-9","article-title":"Recent updates on worldwide gout epidemiology","volume":"39","author":"Mattiuzzi","year":"2020","journal-title":"Clin Rheumatol"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib3","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1186\/s12916-017-0922-5","article-title":"What makes gouty inflammation so variable?","volume":"15","author":"Terkeltaub","year":"2017","journal-title":"BMC Med"},{"issue":"3","key":"10.1016\/j.mayocp.2022.02.027_bib4","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/0002-9343(87)90441-4","article-title":"Asymptomatic hyperuricemia: risks and consequences in the normative aging study","volume":"82","author":"Campion","year":"1987","journal-title":"Am J Med"},{"issue":"11","key":"10.1016\/j.mayocp.2022.02.027_bib5","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1136\/annrheumdis-2019-215933","article-title":"Gout, Hyperuricaemia and Crystal-Associated Disease Network (G-CAN) consensus statement regarding labels and definitions of disease states of gout","volume":"78","author":"Bursill","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib6","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1097\/BOR.0000000000000679","article-title":"Asymptomatic hyperuricemia: is it really asymptomatic?","volume":"32","author":"Yip","year":"2020","journal-title":"Curr Opin Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib7","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1002\/art.40807","article-title":"Contemporary prevalence of gout and hyperuricemia in the United States and decadal trends: the National Health and Nutrition Examination Survey, 2007-2016","volume":"71","author":"Chen-Xu","year":"2019","journal-title":"Arthritis Rheumatol"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib8","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1002\/acr.24180","article-title":"2020 American College of Rheumatology guideline for the management of gout","volume":"72","author":"FitzGerald","year":"2020","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"12","key":"10.1016\/j.mayocp.2022.02.027_bib9","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1080\/15257770.2011.596496","article-title":"Japanese guideline for the management of hyperuricemia and gout: second edition","volume":"30","author":"Yamanaka","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib10","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/sj.jhh.1001941","article-title":"Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in chinese population","volume":"20","author":"Dang","year":"2006","journal-title":"J\u00a0Hum Hypertens"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib11","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1161\/HYPERTENSIONAHA.111.171488","article-title":"Effect of a reduction in uric acid on renal outcomes during losartan treatment: a post hoc analysis of the reduction of endpoints in non-insulin-dependent diabetes mellitus with the angiotensin II antagonist losartan trial","volume":"58","author":"Miao","year":"2011","journal-title":"Hypertension"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib12","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1089\/met.2019.0099","article-title":"Metabolic and cardiovascular effects of switching thiazides to amlodipine in hypertensive patients with and without type 2 diabetes (the diuretics and diabetes control study)","volume":"18","author":"Buscemi","year":"2020","journal-title":"Metab Syndr Relat Disord"},{"issue":"10","key":"10.1016\/j.mayocp.2022.02.027_bib13","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1093\/ndt\/gfg341","article-title":"Amlodipine reduces cyclosporin-induced hyperuricaemia in hypertensive renal transplant recipients","volume":"18","author":"Chanard","year":"2003","journal-title":"Nephrol Dial Transplant"},{"issue":"3","key":"10.1016\/j.mayocp.2022.02.027_bib14","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/BF00558151","article-title":"Antihypertensive and hypouricaemic effects of nitrendipine in chronic renal failure","volume":"36","author":"Weidmann","year":"1989","journal-title":"Eur J Clin Pharmacol"},{"issue":"suppl 2","key":"10.1016\/j.mayocp.2022.02.027_bib15","doi-asserted-by":"crossref","first-page":"113","DOI":"10.2165\/00003495-199300462-00020","article-title":"Long term effects of sustained release verapamil on the renal and systemic haemodynamic parameters in hypertensive patients with mild to severe chronic renal failure","volume":"46","author":"Schohn","year":"1993","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.mayocp.2022.02.027_bib16","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1172\/JCI103905","article-title":"Study of the paradoxical effects of salicylate in low, intermediate and high dosage on the renal mechanisms for excretion of urate in man","volume":"38","author":"Yu","year":"1959","journal-title":"J\u00a0Clin Invest"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib17","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/rheumatology\/39.6.655","article-title":"A\u00a0comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis","volume":"39","author":"Emery","year":"2000","journal-title":"Rheumatology (Oxford)"},{"issue":"16","key":"10.1016\/j.mayocp.2022.02.027_bib18","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.4103\/0366-6999.187848","article-title":"Efficacy of leflunomide, telmisartan, and clopidogrel for immunoglobulin a nephropathy: a randomized controlled trial","volume":"129","author":"Wu","year":"2016","journal-title":"Chin Med J (Engl)"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib19","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1097\/01.rhu.0000081470.31167.8b","article-title":"Influence of leflunomide on renal handling of urate and phosphate in patients with rheumatoid arthritis","volume":"9","author":"Perez-Ruiz","year":"2003","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib20","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/dom.13101","article-title":"Effects of sodium-glucose co-transporter 2 (SGLT2) inhibitors on serum uric acid level: a meta-analysis of randomized controlled trials","volume":"20","author":"Zhao","year":"2018","journal-title":"Diabetes Obes Metab"},{"issue":"12","key":"10.1016\/j.mayocp.2022.02.027_bib21","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40266-015-0328-z","article-title":"Improvement in renal function and reduction in serum uric acid with intensive statin therapy in older patients: a post hoc analysis of the SAGE trial","volume":"32","author":"Deedwania","year":"2015","journal-title":"Drugs Aging"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib22","doi-asserted-by":"crossref","first-page":"1493","DOI":"10.1253\/circj.CJ-10-1281","article-title":"Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial","volume":"75","author":"Saku","year":"2011","journal-title":"Circ J"},{"issue":"9","key":"10.1016\/j.mayocp.2022.02.027_bib23","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1007\/s40265-016-0591-2","article-title":"Impact of statin therapy on plasma uric acid concentrations: a systematic review and meta-analysis","volume":"76","author":"Derosa","year":"2016","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib24","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1016\/j.ijcard.2012.01.092","article-title":"Atorvastatin therapy reduces serum uric acid levels: a meta-analysis of randomized controlled trials","volume":"157","author":"Takagi","year":"2012","journal-title":"Int J Cardiol"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib25","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1097\/00005344-199907000-00010","article-title":"Effect of micronized fenofibrate and losartan combination on uric acid metabolism in hypertensive patients with hyperuricemia","volume":"34","author":"Elisaf","year":"1999","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib26","doi-asserted-by":"crossref","first-page":"2230","DOI":"10.1210\/jc.2007-2467","article-title":"Effect of long-term administration of cross-sex hormone therapy on serum and urinary uric acid in transsexual persons","volume":"93","author":"Yahyaoui","year":"2008","journal-title":"J\u00a0Clin Endocrinol Metab"},{"issue":"5851","key":"10.1016\/j.mayocp.2022.02.027_bib27","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1136\/bmj.1.5851.449","article-title":"Effect of oestrogen therapy on plasma and urinary levels of uric acid","volume":"1","author":"Nicholls","year":"1973","journal-title":"Br Med J"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib28","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1124\/jpet.106.112755","article-title":"Concentration-dependent mode of interaction of angiotensin II receptor blockers with uric acid transporter","volume":"320","author":"Iwanaga","year":"2007","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"5","key":"10.1016\/j.mayocp.2022.02.027_bib29","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1038\/ki.2010.206","article-title":"A\u00a0'complexity' of urate transporters","volume":"78","author":"Wright","year":"2010","journal-title":"Kidney Int"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib30","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/s13075-016-1107-x","article-title":"Lesinurad, a novel, oral compound for gout, acts to decrease serum uric acid through inhibition of urate transporters in the kidney","volume":"18","author":"Miner","year":"2016","journal-title":"Arthritis Res Ther"},{"key":"10.1016\/j.mayocp.2022.02.027_bib31","first-page":"12159","article-title":"Comparative effect of angiotensin II type I receptor blockers on serum uric acid in hypertensive patients with type 2 diabetes mellitus: a retrospective observational study","author":"Nishida","year":"2013","journal-title":"Cardiovasc Diabetol"},{"issue":"11","key":"10.1016\/j.mayocp.2022.02.027_bib32","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/j.jash.2015.07.008","article-title":"A\u00a0pilot study on the impact of a low fructose diet and allopurinol on clinic blood pressure among overweight and prehypertensive subjects: a randomized placebo controlled trial","volume":"9","author":"Madero","year":"2015","journal-title":"J\u00a0Am Soc Hypertens"},{"issue":"10-11","key":"10.1016\/j.mayocp.2022.02.027_bib33","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1159\/000519491","article-title":"Mini review: reappraisal of uric acid in chronic kidney disease","volume":"52","author":"Goldberg","year":"2021","journal-title":"Am J Nephrol"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib34","first-page":"S37","article-title":"Kinetic and metabolic aspects of enalapril action","volume":"2","author":"Lant","year":"1984","journal-title":"J\u00a0Hypertens Suppl"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2022.02.027_bib35","doi-asserted-by":"crossref","first-page":"S56","DOI":"10.1097\/00005344-198507001-00012","article-title":"Effects of captopril, hydrochlorothiazide, and their combination on timed urinary excretions of water and solutes","volume":"7","author":"Leary","year":"1985","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2022.02.027_bib36","doi-asserted-by":"crossref","first-page":"S52","DOI":"10.1097\/00005344-198507001-00011","article-title":"Blood pressure and metabolic responses to hydrochlorothiazide, captopril, and the combination in black and white mild-to-moderate hypertensive patients","volume":"7","author":"Weinberger","year":"1985","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"suppl 1","key":"10.1016\/j.mayocp.2022.02.027_bib37","first-page":"S77","article-title":"Clinical effects of low-dose captopril plus a thiazide diuretic on mild to moderate essential hypertension: a multicenter double-blind comparison with propranolol","volume":"7","year":"1985","journal-title":"J\u00a0Cardiovasc Pharmacol"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib38","first-page":"619","article-title":"Effects of the angiotensin-I converting enzyme inhibitor perindopril on timed urinary excretion of water and solutes in healthy subjects","volume":"44","author":"Reyes","year":"1988","journal-title":"Curr Ther Res"},{"issue":"5","key":"10.1016\/j.mayocp.2022.02.027_bib39","first-page":"1034","article-title":"The effect of ACE inhibitor and angiotensin II receptor antagonist therapy on serum uric acid levels and potassium homeostasis in hypertensive renal transplant recipients treated with CSA","volume":"16","author":"Schmidt","year":"2001","journal-title":"Nephrology"},{"issue":"11","key":"10.1016\/j.mayocp.2022.02.027_bib40","doi-asserted-by":"crossref","first-page":"1343","DOI":"10.1097\/00004872-199511000-00017","article-title":"Comparison of the angiotensin II antagonist losartan with the angiotensin converting enzyme inhibitor enalapril in patients with essential hypertension","volume":"13","author":"Tikkanen","year":"1995","journal-title":"J\u00a0Hypertens"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib41","first-page":"23","article-title":"Molecular mechanism of the urate-lowering effects of calcium channel blockers","volume":"43","author":"Go","year":"2016","journal-title":"Dokkyo J Med Sci"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib42","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1159\/000072054","article-title":"Role of actions of calcium antagonists on efferent arterioles: with special references to glomerular hypertension","volume":"23","author":"Hayashi","year":"2003","journal-title":"Am J Nephrol"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib43","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1536\/ihj.49.723","article-title":"Vasodilatory effect of cilnidipine, an L-type and N-type calcium channel blocker, on rat kidney glomerular arterioles","volume":"49","author":"Konno","year":"2008","journal-title":"Int Heart J"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib44","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1177\/1753944716678538","article-title":"Effect of losartan combined with amlodipine or with a thiazide on uric acid levels in hypertensive patients","volume":"11","author":"Rubio-Guerra","year":"2017","journal-title":"Ther Adv Cardiovasc Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib45","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0021-5198(19)31423-4","article-title":"A\u00a0comparison of the uricosuric effects in rats of diltiazem and derivatives of dihydropyridine (nicardipine and nifedipine)","volume":"74","author":"Sugino","year":"1997","journal-title":"Jpn J Pharmacol"},{"issue":"10","key":"10.1016\/j.mayocp.2022.02.027_bib46","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1111\/jch.12412","article-title":"Effects of the N\/L-type calcium channel blocker cilnidipine on nephropathy and uric acid metabolism in hypertensive patients with chronic kidney disease (j-circle study)","volume":"16","author":"Uchida","year":"2014","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"5","key":"10.1016\/j.mayocp.2022.02.027_bib47","doi-asserted-by":"crossref","first-page":"167","DOI":"10.14740\/cr494w","article-title":"Effects of cilnidipine on heart rate and uric acid metabolism in patients with essential hypertension","volume":"7","author":"Das","year":"2016","journal-title":"Cardiol Res"},{"issue":"11","key":"10.1016\/j.mayocp.2022.02.027_bib48","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1007\/s00380-016-0796-z","article-title":"Long-term effects of L- and N-type calcium channel blocker on uric acid levels and left atrial volume in hypertensive patients","volume":"31","author":"Masaki","year":"2016","journal-title":"Heart Vessels"},{"issue":"7","key":"10.1016\/j.mayocp.2022.02.027_bib49","doi-asserted-by":"crossref","first-page":"470","DOI":"10.3109\/10641963.2012.666600","article-title":"Effects of cilnidipine on serum uric acid level and urinary nitrogen monoxide excretion in patients with hypertension","volume":"34","author":"Hamada","year":"2012","journal-title":"Clin Exp Hypertens"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib50","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/art.38203","article-title":"Use of diuretics and risk of incident gout: a population-based case-control study","volume":"66","author":"Bruderer","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.mayocp.2022.02.027_bib51","doi-asserted-by":"crossref","first-page":"d8190","DOI":"10.1136\/bmj.d8190","article-title":"Antihypertensive drugs and risk of incident gout among patients with hypertension: population based case-control study","volume":"344","author":"Choi","year":"2012","journal-title":"BMJ"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib52","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/S0002-9343(03)00436-4","article-title":"Early and late effects of low-dose aspirin on renal function in elderly patients","volume":"115","author":"Segal","year":"2003","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib53","first-page":"499","article-title":"Human renal urate transpoter urat1 mediates the transport of salicylate. Article in Japanese","volume":"52","author":"Ohtsu","year":"2010","journal-title":"Nihon Jinzo Gakkai Shi"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib54","first-page":"507","article-title":"Piroxicam in the treatment of acute gout: a multicentre open study in general practice","volume":"7","author":"Murphy","year":"1979","journal-title":"J\u00a0Int Med Res"},{"issue":"3","key":"10.1016\/j.mayocp.2022.02.027_bib55","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1007\/BF02041396","article-title":"Effect of nonsteroidal anti-inflammatory drugs on the renal excretion of uric acid","volume":"2","author":"Tiitinen","year":"1983","journal-title":"Clin Rheumatol"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib56","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1111\/j.1440-1797.2010.01368.x","article-title":"Interactions of urate transporter URAT1 in human kidney with uricosuric drugs","volume":"16","author":"Shin","year":"2011","journal-title":"Nephrology (Carlton)"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/anr.1780320102","article-title":"The mechanisms of action of nonsteroidal antiinflammatory drugs","volume":"32","author":"Abramson","year":"1989","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.mayocp.2022.02.027_bib58","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1002\/bdd.1909","article-title":"SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria","volume":"35","author":"Chino","year":"2014","journal-title":"Biopharm Drug Dispos"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib59","doi-asserted-by":"crossref","first-page":"F77","DOI":"10.1152\/ajprenal.00555.2014","article-title":"Glycosuria-mediated urinary uric acid excretion in patients with uncomplicated type 1 diabetes mellitus","volume":"308","author":"Lytvyn","year":"2015","journal-title":"Am J Physiol-Renal Physiol"},{"issue":"3","key":"10.1016\/j.mayocp.2022.02.027_bib60","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1001\/jama.1993.03510030078038","article-title":"Uric acid metabolism and tubular sodium handling: results from a population-based study","volume":"270","author":"Cappuccio","year":"1993","journal-title":"JAMA"},{"issue":"4-6","key":"10.1016\/j.mayocp.2022.02.027_bib61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1080\/15257771003741323","article-title":"Effects of three strong statins (atorvastatin, pitavastatin, and rosuvastatin) on serum uric acid levels in dyslipidemic patients","volume":"29","author":"Ogata","year":"2010","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib62","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1185\/030079906X112462","article-title":"Treating to target patients with primary hyperlipidaemia: comparison of the effects of atorvastatin and rosuvastatin (the ATOROS study)","volume":"22","author":"Milionis","year":"2006","journal-title":"Curr Med Res Opin"},{"issue":"7-8","key":"10.1016\/j.mayocp.2022.02.027_bib63","doi-asserted-by":"crossref","first-page":"1466","DOI":"10.1345\/aph.1H064","article-title":"Rhabdomyolysis in a patient treated with colchicine and atorvastatin","volume":"40","author":"Tufan","year":"2006","journal-title":"Ann Pharmacother"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib64","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/0026-0495(86)90152-6","article-title":"Sex differences in uric acid metabolism in adults: evidence for a lack of influence of estradiol-17 beta (e2) on the renal handling of urate","volume":"35","author":"Ant\u00f3n","year":"1986","journal-title":"Metabolism"},{"issue":"6730","key":"10.1016\/j.mayocp.2022.02.027_bib65","doi-asserted-by":"crossref","first-page":"975","DOI":"10.1136\/bmj.300.6730.975","article-title":"Relation between dose of bendrofluazide, antihypertensive effect, and adverse biochemical effects","volume":"300","author":"Carlsen","year":"1990","journal-title":"BMJ"},{"issue":"5-6","key":"10.1016\/j.mayocp.2022.02.027_bib66","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1023\/B:CARD.0000015855.02485.e3","article-title":"Cardiovascular drugs and serum uric acid","volume":"17","author":"Reyes","year":"2003","journal-title":"Cardiovasc Drugs Ther"},{"issue":"3","key":"10.1016\/j.mayocp.2022.02.027_bib67","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1001\/archinte.1996.00440030072009","article-title":"Losartan and low-dose hydrochlorothiazide in patients with essential hypertension: a double-blind, placebo-controlled trial of concomitant administration compared with individual components","volume":"156","author":"MacKay","year":"1996","journal-title":"Arch Intern Med"},{"issue":"3","key":"10.1016\/j.mayocp.2022.02.027_bib68","first-page":"467-475","article-title":"Multicentre randomized cross-over double-blind comparison between chlorthalidone and slow-release oxprenolol in mild-to-moderate hypertension","volume":"35","author":"Pollavini","year":"1984","journal-title":"Curr Ther Res Clin Exp"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib69","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.0954-6820.1985.tb08843.x","article-title":"Atenolol versus bendroflumethiazide in middle-aged and elderly hypertensives","volume":"218","author":"Andersen","year":"1985","journal-title":"Acta Med Scand"},{"issue":"9","key":"10.1016\/j.mayocp.2022.02.027_bib70","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1093\/ajh\/hpx113","article-title":"Metoprolol increases uric acid and risk of gout in African Americans with chronic kidney disease attributed to hypertension","volume":"30","author":"Juraschek","year":"2017","journal-title":"Am J Hypertens"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib71","first-page":"154","article-title":"Hyperuricemia & arthralgia during pyrazinamide therapy in patients with pulmonary tuberculosis","volume":"22","author":"Inayat","year":"2016","journal-title":"Pak J Chest Med"},{"issue":"14","key":"10.1016\/j.mayocp.2022.02.027_bib72","doi-asserted-by":"crossref","first-page":"761","DOI":"10.1056\/NEJM197204062861407","article-title":"Hyperuricemia due to ethambutol","volume":"286","author":"Postlethwaite","year":"1972","journal-title":"N\u00a0Engl J Med"},{"issue":"7","key":"10.1016\/j.mayocp.2022.02.027_bib73","doi-asserted-by":"crossref","first-page":"3119","DOI":"10.1016\/j.transproceed.2005.08.042","article-title":"Influence of cyclosporine and tacrolimus on serum uric acid levels in stable kidney transplant recipients","volume":"37","author":"Kanbay","year":"2005","journal-title":"Transplant Proc"},{"issue":"5","key":"10.1016\/j.mayocp.2022.02.027_bib74","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1016\/j.semarthrit.2014.10.008","article-title":"The effect of initiating pharmacologic insulin on serum uric acid levels in patients with diabetes: a matched cohort analysis","volume":"44","author":"MacFarlane","year":"2015","journal-title":"Semin Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.mayocp.2022.02.027_bib75","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1507\/endocrj.EJ13-0203","article-title":"Testosterone replacement elevates the serum uric acid levels in patients with female to male gender identity disorder","volume":"60","author":"Kurahashi","year":"2013","journal-title":"Endocr J"},{"issue":"3","key":"10.1016\/j.mayocp.2022.02.027_bib76","first-page":"191","article-title":"Enhancement of renal excretion of uric acid during long-term thiazide therapy","volume":"16","author":"Pak","year":"1978","journal-title":"Invest Urol"},{"issue":"5951","key":"10.1016\/j.mayocp.2022.02.027_bib77","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1136\/bmj.1.5951.197","article-title":"Effect of different doses of chlorthalidone on blood pressure, serum potassium, and serum urate","volume":"1","author":"Bengtsson","year":"1975","journal-title":"Br Med J"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib78","first-page":"120","article-title":"Renal excretory actions of furosemide, of hydrochlorothiazide and of the vasodilator flosequinan in healthy subjects","volume":"18","author":"Leary","year":"1990","journal-title":"J\u00a0Int Med Res"},{"issue":"11","key":"10.1016\/j.mayocp.2022.02.027_bib79","doi-asserted-by":"crossref","first-page":"702","DOI":"10.1016\/0002-9149(89)90255-5","article-title":"Effects of reduction in drugs or dosage after long-term control of systemic hypertension","volume":"63","author":"Freis","year":"1989","journal-title":"Am J Cardiol"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib80","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1161\/01.CIR.51.6.1107","article-title":"Return of elevated blood pressure after withdrawal of antihypertensive drugs","volume":"51","author":"Freis","year":"1975","journal-title":"Circulation"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib81","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1016\/0002-8703(92)90075-7","article-title":"Comparison of withdrawing antihypertensive therapy between diuretics and angiotensin converting enzyme inhibitors in essential hypertensives","volume":"124","author":"Takata","year":"1992","journal-title":"Am Heart J"},{"issue":"9","key":"10.1016\/j.mayocp.2022.02.027_bib82","doi-asserted-by":"crossref","first-page":"639","DOI":"10.1111\/j.1751-7176.2011.00512.x","article-title":"Thiazide and loop diuretics","volume":"13","author":"Sica","year":"2011","journal-title":"J\u00a0Clin Hypertens (Greenwich)"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib83","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.semnephrol.2011.09.009","article-title":"Metabolic complications associated with use of diuretics","volume":"31","author":"Palmer","year":"2011","journal-title":"Semin Nephrol"},{"issue":"3","key":"10.1016\/j.mayocp.2022.02.027_bib84","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1124\/jpet.103.059139","article-title":"Interactions of human organic anion transporters with diuretics","volume":"308","author":"Hasannejad","year":"2004","journal-title":"J\u00a0Pharmacol Exp Ther"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib85","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1681\/ASN.2006040415","article-title":"Human renal organic anion transporter 4 operates as an asymmetric urate transporter","volume":"18","author":"Hagos","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib86","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1172\/JCI107931","article-title":"The influence of the extracellular fluid volume on the tubular reabsorption of uric acid","volume":"55","author":"Weinman","year":"1975","journal-title":"J\u00a0Clin Invest"},{"issue":"7","key":"10.1016\/j.mayocp.2022.02.027_bib87","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1038\/bjp.2008.343","article-title":"Effect of hypouricaemic and hyperuricaemic drugs on the renal urate efflux transporter, multidrug resistance protein 4","volume":"155","author":"El-Sheikh","year":"2008","journal-title":"Br J Pharmacol"},{"issue":"12","key":"10.1016\/j.mayocp.2022.02.027_bib88","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1080\/15257770.2011.616564","article-title":"Apical voltage-driven urate efflux transporter NPT4 in renal proximal tubule","volume":"30","author":"Jutabha","year":"2011","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib89","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1111\/j.0954-6820.1976.tb06770.x","article-title":"Antihypertensive effect and side-effects of bendroflumethiazide and propranolol","volume":"199","author":"Berglund","year":"1976","journal-title":"Acta Med Scand"},{"issue":"2-3","key":"10.1016\/j.mayocp.2022.02.027_bib90","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/j.1552-4604.1984.tb02772.x","article-title":"The combined alpha- and beta-adrenergic blocker labetalol and propranolol in the treatment of high blood pressure: similarities and differences","volume":"24","author":"Weber","year":"1984","journal-title":"J\u00a0Clin Pharmacol"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib91","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/BF00637506","article-title":"Sotalol and metoprolol comparison of their anti-hypertensive effect","volume":"21","author":"Andersson","year":"1981","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.mayocp.2022.02.027_bib92","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1055\/s-0042-113183","article-title":"Effect of antihypertensive drugs on uric acid metabolism in patients with hypertension: cross-sectional cohort study","volume":"66","author":"Ueno","year":"2016","journal-title":"Drug Res (Stuttg)"},{"issue":"7","key":"10.1016\/j.mayocp.2022.02.027_bib93","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1097\/RHU.0000000000000297","article-title":"Effect of antituberculous drugs on serum uric acid and urine uric acid excretion","volume":"21","author":"Louthrenoo","year":"2015","journal-title":"J\u00a0Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib94","first-page":"575","article-title":"Renal function in gout, 3: estimation of tubular secretion and reabsorption of uric acid by use of pyrazinamide (pyrazinoic acid)","volume":"47","author":"Gutman","year":"1969","journal-title":"Am J Med"},{"issue":"2 Part 1","key":"10.1016\/j.mayocp.2022.02.027_bib125","first-page":"289","article-title":"The occurrence of hyperuricemia during pyrazinamide-isoniazid therapy","volume":"74","author":"Cullen","year":"1956","journal-title":"Am Rev Tuberc"},{"issue":"24","key":"10.1016\/j.mayocp.2022.02.027_bib95","doi-asserted-by":"crossref","first-page":"16332","DOI":"10.1074\/jbc.M800737200","article-title":"Identification of a new urate and high affinity nicotinate transporter, hOAT10 (SLC22A13)","volume":"283","author":"Bahn","year":"2008","journal-title":"J\u00a0Biol Chem"},{"issue":"6887","key":"10.1016\/j.mayocp.2022.02.027_bib96","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1038\/nature742","article-title":"Molecular identification of a renal urate\u2013anion exchanger that regulates blood urate levels","volume":"417","author":"Enomoto","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.mayocp.2022.02.027_bib97","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1146\/annurev-physiol-021113-170343","article-title":"The molecular physiology of uric acid homeostasis","volume":"77","author":"Mandal","year":"2015","journal-title":"Annu Rev Physiol"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib98","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/0007-0971(80)90080-7","article-title":"Acute gouty arthritis following ethambutol therapy","volume":"74","author":"Khanna","year":"1980","journal-title":"Br J Dis Chest"},{"issue":"10","key":"10.1016\/j.mayocp.2022.02.027_bib99","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1111\/1756-185X.13697","article-title":"Clinical features and risk factors for gout attacks during anti-tuberculosis treatment: a case-control study in South Korea","volume":"22","author":"Ha","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib100","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1002\/1529-0131(200001)43:1<103::AID-ANR13>3.0.CO;2-C","article-title":"The effect of mini-dose aspirin on renal function and uric acid handling in elderly patients","volume":"43","author":"Caspi","year":"2000","journal-title":"Arthritis Rheum"},{"issue":"5","key":"10.1016\/j.mayocp.2022.02.027_bib101","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1681\/ASN.V115974","article-title":"Renal transplant-associated hyperuricemia and gout","volume":"11","author":"Clive","year":"2000","journal-title":"J\u00a0Am Soc Nephrol"},{"issue":"9256","key":"10.1016\/j.mayocp.2022.02.027_bib102","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1016\/S0140-6736(00)04055-1","article-title":"Replacement of calcineurin inhibitors with mycophenolate mofetil in liver-transplant patients with renal dysfunction: a randomised controlled study","volume":"357","author":"Schlitt","year":"2001","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.mayocp.2022.02.027_bib103","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1056\/NEJM198908033210504","article-title":"Cyclosporine-induced hyperuricemia and gout","volume":"321","author":"Lin","year":"1989","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.mayocp.2022.02.027_bib104","first-page":"124","article-title":"Hyperuricemia in kidney transplantation","volume":"147","author":"Perico","year":"2005","journal-title":"Contrib Nephrol"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib105","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/0002-9343(92)90104-J","article-title":"Hyperuricemia and gout among heart transplant recipients receiving cyclosporine","volume":"92","author":"Burack","year":"1992","journal-title":"Am J Med"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib106","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1097\/01.tp.0000276959.56959.69","article-title":"Replacement of calcineurin-inhibitors with sirolimus as primary immunosuppression in stable cardiac transplant recipients","volume":"84","author":"Raichlin","year":"2007","journal-title":"Transplantation"},{"issue":"5","key":"10.1016\/j.mayocp.2022.02.027_bib107","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0272-6386(87)80103-8","article-title":"The incidence of gout in renal transplant recipients","volume":"10","author":"West","year":"1987","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"10.1016\/j.mayocp.2022.02.027_bib108","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1159\/000188609","article-title":"Impairment of tubular secretion of urate in renal transplant patients on cyclosporine","volume":"70","author":"Marc\u00e9n","year":"1995","journal-title":"Nephron"},{"issue":"4","key":"10.1016\/j.mayocp.2022.02.027_bib109","first-page":"564","article-title":"Comparative analysis of azathioprine versus cyclosporine-based therapy in primary haplo-identical live-donor kidney transplantation: a 20-year experience","volume":"19","author":"Gheith","year":"2008","journal-title":"Saudi J Kidney Dis Transpl"},{"issue":"7","key":"10.1016\/j.mayocp.2022.02.027_bib110","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.1097\/00007890-199710150-00027","article-title":"Safety of the mycophenolate mofetil-allopurinol combination in kidney transplant recipients with gout","volume":"64","author":"Jacobs","year":"1997","journal-title":"Transplantation"},{"issue":"suppl_1","key":"10.1016\/j.mayocp.2022.02.027_bib111","first-page":"i180","article-title":"E19. Rapid response to benzbromarone for gout in a renal transplant patient","volume":"54","author":"Omar","year":"2015","journal-title":"Rheumatology"},{"issue":"18","key":"10.1016\/j.mayocp.2022.02.027_bib112","doi-asserted-by":"crossref","first-page":"2593","DOI":"10.2165\/00003495-200565180-00004","article-title":"Gout in solid organ transplantation: a challenging clinical problem","volume":"65","author":"Stamp","year":"2005","journal-title":"Drugs"},{"issue":"8","key":"10.1016\/j.mayocp.2022.02.027_bib113","doi-asserted-by":"crossref","first-page":"643","DOI":"10.2165\/00002018-200831080-00002","article-title":"A\u00a0benefit-risk assessment of benzbromarone in the treatment of gout: was its withdrawal from the market in the best interest of patients?","volume":"31","author":"Lee","year":"2008","journal-title":"Drug Saf"},{"issue":"2","key":"10.1016\/j.mayocp.2022.02.027_bib114","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1016\/j.rdc.2006.02.006","article-title":"Renal urate transport.","volume":"32","author":"Mount","year":"2006","journal-title":"Rheumatic Disease Clinics of North America"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib115","doi-asserted-by":"crossref","first-page":"17","DOI":"10.3181\/00379727-127-32610","article-title":"The effect of lactate infusion on serum uric acid","volume":"127","author":"Burch","year":"1968","journal-title":"Proc Soc Exp Biol Med"},{"issue":"7","key":"10.1016\/j.mayocp.2022.02.027_bib116","doi-asserted-by":"crossref","first-page":"499","DOI":"10.7326\/0003-4819-143-7-200510040-00009","article-title":"Pathogenesis of gout","volume":"143","author":"Choi","year":"2005","journal-title":"Ann Intern Med"},{"issue":"9417","key":"10.1016\/j.mayocp.2022.02.027_bib117","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1016\/S0140-6736(04)16000-5","article-title":"Alcohol intake and risk of incident gout in men: a prospective study","volume":"363","author":"Choi","year":"2004","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.mayocp.2022.02.027_bib118","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1002\/art.20821","article-title":"Beer, liquor, and wine consumption and serum uric acid level: the Third National Health and Nutrition Examination Survey","volume":"51","author":"Choi","year":"2004","journal-title":"Arthritis Rheum"},{"issue":"7","key":"10.1016\/j.mayocp.2022.02.027_bib119","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1080\/15257770.2010.494651","article-title":"The effect of testosterone upon the urate reabsorptive transport system in mouse kidney","volume":"29","author":"Hosoyamada","year":"2010","journal-title":"Nucleosides Nucleotides Nucleic Acids"},{"key":"10.1016\/j.mayocp.2022.02.027_bib120","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1016\/0002-9343(65)90048-3","article-title":"The distribution of serum uric acid values in a population unselected as to gout or hyperuricemia: Tecumseh, Michigan 1959-1960","volume":"39","author":"Mikkelsen","year":"1965","journal-title":"Am J Med"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib121","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1186\/s12958-018-0419-x","article-title":"Association between the prevalence of hyperuricemia and reproductive hormones in polycystic ovary syndrome","volume":"16","author":"Mu","year":"2018","journal-title":"Reprod Biol Endocrinol"},{"issue":"1","key":"10.1016\/j.mayocp.2022.02.027_bib122","first-page":"198","article-title":"The relationship of sex steroids to uric acid levels in plasma and urine","volume":"85","author":"Adamopoulos","year":"1977","journal-title":"Acta Endocrinol (Copenh)"},{"issue":"5","key":"10.1016\/j.mayocp.2022.02.027_bib123","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1006\/pmed.1996.0096","article-title":"Relationships between serum uric acid and lipids in healthy subjects","volume":"25","author":"Russo","year":"1996","journal-title":"Prev Med"},{"issue":"5","key":"10.1016\/j.mayocp.2022.02.027_bib124","doi-asserted-by":"crossref","first-page":"R116","DOI":"10.1186\/ar2519","article-title":"Menopause, postmenopausal hormone use and serum uric acid levels in US women: the Third National Health and Nutrition Examination Survey","volume":"10","author":"Hak","year":"2008","journal-title":"Arthritis Res Ther"}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622001318?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619622001318?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,1,23]],"date-time":"2024-01-23T09:55:28Z","timestamp":1706003728000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619622001318"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,7]]},"references-count":125,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2022,7]]}},"alternative-id":["S0025619622001318"],"URL":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.02.027","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2022,7]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Lowering and Raising Serum Urate Levels: Off-Label Effects of Commonly Used Medications","name":"articletitle","label":"Article Title"},{"value":"Mayo Clinic Proceedings","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mayocp.2022.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Mayo Foundation for Medical Education and Research","name":"copyright","label":"Copyright"}]}}